JP2000500014A - ピヒア・メタノリカ中で異種ポリペプチドを生産するための組成物と方法 - Google Patents
ピヒア・メタノリカ中で異種ポリペプチドを生産するための組成物と方法Info
- Publication number
- JP2000500014A JP2000500014A JP9518345A JP51834597A JP2000500014A JP 2000500014 A JP2000500014 A JP 2000500014A JP 9518345 A JP9518345 A JP 9518345A JP 51834597 A JP51834597 A JP 51834597A JP 2000500014 A JP2000500014 A JP 2000500014A
- Authority
- JP
- Japan
- Prior art keywords
- gene
- methanolica
- dna
- nucleotide
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 31
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 29
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 29
- 241001452677 Ogataea methanolica Species 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 title claims description 54
- 239000000203 mixture Substances 0.000 title description 15
- 108020004414 DNA Proteins 0.000 claims abstract description 183
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 133
- 239000003550 marker Substances 0.000 claims abstract description 46
- 238000013518 transcription Methods 0.000 claims abstract description 29
- 230000035897 transcription Effects 0.000 claims abstract description 28
- 102000053602 DNA Human genes 0.000 claims abstract description 23
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 142
- 239000002773 nucleotide Substances 0.000 claims description 66
- 125000003729 nucleotide group Chemical group 0.000 claims description 66
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 37
- 239000008103 glucose Substances 0.000 claims description 37
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 31
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 30
- 102000004169 proteins and genes Human genes 0.000 claims description 30
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 17
- 229910052799 carbon Inorganic materials 0.000 claims description 17
- 108010025188 Alcohol oxidase Proteins 0.000 claims description 12
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 10
- 108091026890 Coding region Proteins 0.000 claims description 9
- 238000012258 culturing Methods 0.000 claims description 9
- 108010053835 Catalase Proteins 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 108010067193 Formaldehyde transketolase Proteins 0.000 claims description 7
- 108090000698 Formate Dehydrogenases Proteins 0.000 claims description 6
- 241000233866 Fungi Species 0.000 claims description 4
- 102000016938 Catalase Human genes 0.000 claims description 3
- 230000010261 cell growth Effects 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000003306 harvesting Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 101150096273 ADE2 gene Proteins 0.000 claims 8
- 229940081969 saccharomyces cerevisiae Drugs 0.000 claims 6
- 240000004922 Vigna radiata Species 0.000 claims 2
- 101000616718 Homo sapiens Sialate O-acetylesterase Proteins 0.000 claims 1
- 241000566194 Methylomonas methanolica Species 0.000 claims 1
- 102100021837 Sialate O-acetylesterase Human genes 0.000 claims 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 14
- 210000004027 cell Anatomy 0.000 description 187
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 32
- 239000002609 medium Substances 0.000 description 28
- 230000009466 transformation Effects 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 20
- 239000000047 product Substances 0.000 description 19
- 238000004520 electroporation Methods 0.000 description 18
- 239000000872 buffer Substances 0.000 description 17
- 101150001038 ade gene Proteins 0.000 description 16
- 230000035772 mutation Effects 0.000 description 16
- 229910052757 nitrogen Inorganic materials 0.000 description 16
- 239000000243 solution Substances 0.000 description 13
- 230000012010 growth Effects 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 230000005684 electric field Effects 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 235000020958 biotin Nutrition 0.000 description 10
- 239000011616 biotin Substances 0.000 description 10
- 229960002685 biotin Drugs 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 241000235648 Pichia Species 0.000 description 9
- 235000002639 sodium chloride Nutrition 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000000855 fermentation Methods 0.000 description 8
- 230000004151 fermentation Effects 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 239000011573 trace mineral Substances 0.000 description 8
- 235000013619 trace mineral Nutrition 0.000 description 8
- 229930024421 Adenine Natural products 0.000 description 7
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 7
- 239000007983 Tris buffer Substances 0.000 description 7
- 239000008186 active pharmaceutical agent Substances 0.000 description 7
- 229960000643 adenine Drugs 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 231100000350 mutagenesis Toxicity 0.000 description 7
- 238000002703 mutagenesis Methods 0.000 description 7
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 7
- 230000001131 transforming effect Effects 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- 235000015097 nutrients Nutrition 0.000 description 6
- 229960000988 nystatin Drugs 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000006798 recombination Effects 0.000 description 5
- 238000005215 recombination Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 108091022930 Glutamate decarboxylase Proteins 0.000 description 4
- 102100035902 Glutamate decarboxylase 1 Human genes 0.000 description 4
- 241000235058 Komagataella pastoris Species 0.000 description 4
- 241000320412 Ogataea angusta Species 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 101100447572 Schizosaccharomyces pombe (strain 972 / ATCC 24843) gad8 gene Proteins 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 238000013507 mapping Methods 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- 239000002028 Biomass Substances 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 241000206602 Eukaryota Species 0.000 description 3
- 101100246753 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) pyrF gene Proteins 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- 108091027981 Response element Proteins 0.000 description 3
- 101150050575 URA3 gene Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 3
- 239000003471 mutagenic agent Substances 0.000 description 3
- 230000003505 mutagenic effect Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 238000007747 plating Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methanesulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 description 2
- 101100223318 Homo sapiens GAD2 gene Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102100027330 Phosphoribosylaminoimidazole carboxylase Human genes 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 102100038583 Secreted Ly-6/uPAR-related protein 1 Human genes 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 231100000225 lethality Toxicity 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 231100000707 mutagenic chemical Toxicity 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 108010035774 phosphoribosylaminoimidazole carboxylase Proteins 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000006152 selective media Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
- SEHFUALWMUWDKS-UHFFFAOYSA-N 5-fluoroorotic acid Chemical compound OC(=O)C=1NC(=O)NC(=O)C=1F SEHFUALWMUWDKS-UHFFFAOYSA-N 0.000 description 1
- FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical group NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229930195730 Aflatoxin Natural products 0.000 description 1
- XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 101100437119 Arabidopsis thaliana AUG2 gene Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 1
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 101100364969 Dictyostelium discoideum scai gene Proteins 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241001288713 Escherichia coli MC1061 Species 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 102100035857 Glutamate decarboxylase 2 Human genes 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100223310 Homo sapiens GAD1 gene Proteins 0.000 description 1
- 101000873786 Homo sapiens Glutamate decarboxylase 2 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 108010020056 Hydrogenase Proteins 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 101100364971 Mus musculus Scai gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 108700025832 Serum Response Element Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 1
- 102000036693 Thrombopoietin Human genes 0.000 description 1
- 108010041111 Thrombopoietin Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 1
- 108700015934 Triose-phosphate isomerases Proteins 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 238000003848 UV Light-Curing Methods 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- 241000222124 [Candida] boidinii Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000005409 aflatoxin Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 101150074548 blaI gene Proteins 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003990 capacitor Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000002962 chemical mutagen Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- CRQQGFGUEAVUIL-UHFFFAOYSA-N chlorothalonil Chemical compound ClC1=C(Cl)C(C#N)=C(Cl)C(C#N)=C1Cl CRQQGFGUEAVUIL-UHFFFAOYSA-N 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- UNWBBBCIZYEGIZ-UHFFFAOYSA-N denin Natural products C1CC2(C)C3C(O)C(O)C4(C)C(C(O)C)CCC4(O)C3CCC2CC1OC(C(C1O)O)OC(C)C1OC1OC(CO)C(O)C(O)C1O UNWBBBCIZYEGIZ-UHFFFAOYSA-N 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- -1 ethyl-2-chloroethyl Chemical group 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- MFPODHWDVFPSKC-BTVCFUMJSA-N methanol;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O MFPODHWDVFPSKC-BTVCFUMJSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 229940049018 mycostatin Drugs 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 102220201851 rs143406017 Human genes 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000012807 shake-flask culturing Methods 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000011172 small scale experimental method Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- DNYWZCXLKNTFFI-UHFFFAOYSA-N uranium Chemical compound [U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U] DNYWZCXLKNTFFI-UHFFFAOYSA-N 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 108010082737 zymolyase Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
- C12N9/60—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi from yeast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.次の作用可能に連結された要素: ピヒア・メタノリカ(Pichia methanolica)遺伝子の転写プロモーター; P.メタノリカにとって異種のポリペプチドをコードするDNAセグメント; P.メタノリカ遺伝子の転写ターミネーター;および 選択マーカー を含んで成るDNA構成物。 2.前記転写プロモーターがメタノール誘導性P.メタノリカ遺伝子のプロモ ーターである、請求項1に記載のDNA構成物。 3.前記プロモーターが、P.メタノリカのアルコールオキシダーゼ、ジヒド ロキシアセトンシンターゼ、ホルメートデヒドロゲナーゼおよびカタラーゼ遺伝 子から成る群より選ばれた遺伝子のプロモーターである、請求項2に記載のDN A構成物。 4.前記プロモーターが配列番号2のヌクレオチド24からヌクレオチド1354ま でに示されるヌクレオチド配列を含んで成る、請求項3に記載のDNA構成物。 5.前記プロモーターが配列番号9のヌクレオチド91からヌクレオチド169 ま でに示されるヌクレオチド配列を含んで成る、請求項3に記載のDNA構成物。 6.前記選択マーカーがP.メタノリカ遺伝子である、請求項1に記載のDN A構成物。 7.前記マーカーがP.メタノリカADE2遺伝子である、請求項6に記載のDN A構成物。 8.前記ADE2遺伝子が配列番号1のヌクレオチド407 からヌクレ オチド2851までに示されるヌクレオチド配列を含んで成る、請求項7に記載のD NA構成物。 9.前記選択マーカーがP.メタノリカ以外の真菌由来の遺伝子である、請求 項1に記載のDNA構成物。 10.前記選択マーカーがサッカロミセス・セレビシェ(Saccharomyces cerevi siae )遺伝子である、請求項9に記載のDNA構成物。 11.直鎖状分子である、請求項1に記載のDNA構成物。 12.前記選択マーカーが優性選択マーカーである、請求項1に記載のDNA構 成物。 13.請求項1に記載のDNA構成物を含有するP.メタノリカ細胞であって、 該DNAセグメントを発現するP.メタノリカ細胞。 14.前記DNA構成物が宿主細胞のゲノム中に組み込まれる、請求項13に記載 のP.メタノリカ細胞。 15.前記転写プロモーターがメタノール誘導性P.メタノリカ遺伝子のプロモ ーターである、請求項13に記載の細胞。 16.前記プロモーターが、P.メタノリカのアルコールオキシダーゼ、ジヒド ロキシアセトンシンターゼ、ホルメートデヒドロゲナーゼおよびカタラーゼ遺伝 子から成る群より選ばれた遺伝子のプロモーターである、請求項15に記載の細胞 。 17.前記プロモーターが配列番号2のヌクレオチド24からヌクレオチド1354ま でに示されるヌクレオチド配列を含んで成る、請求項16に記載の細胞。 18.前記プロモーターが配列番号9のヌクレオチド91からヌクレオチド169 ま でに示されるヌクレオチド配列を含んで成る、請求項16に記載の細胞。 19.前記選択マーカーがP.メタノリカ遺伝子である、請求項13 に記載の細胞。 20.前記マーカーがP.メタノリカADE2遺伝子である、請求項19に記載の細胞 。 21.前記ADE2遺伝子が配列番号1のヌクレオチド407 からヌクレオチド2851ま でに示されるヌクレオチド配列を含んで成る、請求項20に記載の細胞。 22.前記選択マーカーがP.メタノリカ以外の真菌由来の遺伝子である、請求 項13に記載の細胞。 23.前記選択マーカーがサッカロミセス・セレビシェ(Saccharomyces cerevi siae )の遺伝子である、請求項22に記載の細胞。 24.前記選択マーカーが優性選択マーカーである、請求項13に記載の細胞。 25.高等真核生物ポリペブチドをピヒア・メタノリカ(Pichia methanolica) 中で生産する方法であって、 (a) 次の作用可能に連結された要素: (i)メタノール誘導性P.メタノリカ遺伝子の転写プロモーターを含んで成 る第一のDNAセグメント; (ii)高等真核生物ポリペプチドをコードする第二のDNAセグメント; (iii)P.メタノリカ遺伝子の転写ターミネーターを含んで成る第三のDN Aセグメント;および (iv)選択マーカー を含んで成る異種DNA構成物が導入されたP.メタノリカ細胞を、前記第二の DNAセグメントが発現される条件下で培養し;そして (b) 前記第二のDNAセグメントによりコードされるポリペプチドを回収する ことを含んで成る方法。 26.前記転写プロモーターが、P.メタノリカ構造遺伝子コード配列の5′側 で且つ隣接した1.5 キロ塩基対領域の中に含まれるDNAゼグメントである、請 求項25に記載の方法。 27.前記構造遺伝子がアルコールオキシダーゼ、ジヒドロキシアセトンシンタ ーゼ、ホルメートデヒドロゲナーゼおよびカタラーゼから成る群より選ばれた酵 素をコードする、請求項26に記載の方法。 28.前記第一のDNAセグメントが、配列番号2のヌクレオチド24からヌクレ オチド1354までに示されるヌクレオチド配列を含んで成る、請求項27に記載の方 法。 29.前記第一のDNAセグメントが、配列番号9のヌクレオチド91からヌクレ オチド169 までに示されるヌクレオチド配列を含んで成る、請求項27に記載の方 法。 30.前記転写ターミネーターが、P.メタノリカ構造遺伝子コード配列の3′ 側で且つ隣接した500 塩基対領域の中に含まれる配列である、請求項25に記載の 方法。 31.前記培養段階がメタノールと抑制炭素源を含んで成る液体培地中で行われ る、請求項25に記載の方法。 32.前記抑制炭素源がグルコースである、請求項31に記載の方法。 33.前記ポリペプチド回収段階の前に前記細胞が1lあたり80〜400 グラムの 湿潤細胞ペーストの密度に培養される、請求項25に記載の方法。 34.前記選択マーカーがP.メタノリカ遺伝子である、請求項25に記載の方法 。 35.前記選択マーカーがP.メタノリカADE2遺伝子である、請求項34に記載の 方法。 36.前記ADE2遺伝子が配列番号1のヌクレオチド407 からヌクレ オチド2851までに示されるヌクレオチド配列を含んで成る、請求項35に記載の方 法。 37.前記選択マーカーがP.メタノリカ以外の真菌由来の遺伝子である、請求 項25に記載の方法。 38.前記選択マーカーがサッカロミセス・セレビシェ(Saccharomyces cerevi siae )の遺伝子である、請求項37に記載の方法。 39.前記選択マーカーが優性選択マーカーである、請求項25に記載の方法。 40.前記ポリペプチドがヒトポリペプチドである、請求項25に記載の方法。 41.前記異種DNA分子が直鎖状DNA分子である、請求項25の記載の方法。 42.外来DNA構成物を含有するピヒア・メタノリカ(Pichia methanolica) 細胞の調製方法であって、 (a) 次の作用可能に連結された要素: (i)メタノール誘導性P.メタノリカ遺伝子の転写プロモーターを含んで成 る第一のDNAセグメント; (ii)高等真核生物ポリペプチドをコードする第二のDNAセグメント; (iii)P.メタノリカ遺伝子の転写ターミネーターを含んで成る第三のDN Aセグメント;および (iv)選択マーカー を含んで成るDNA構成物をP.メタノリカ細胞中に導入し; (b) 段階(a)からのP.メタノリカ細胞を、前記DNA構成物を含有する細胞 の増殖について選択する条件下で培養し;そして (c) 前記選択条件下で増殖する細胞を回収する ことを含んで成る方法。 43.前記選択マーカーがP.メタノリカ遺伝子である、請求項42に記載の方法 。 44.前記選択マーカーがP.メタノリカADE2遺伝子である、請求項43に記載の 細胞。 45.前記ADE2遺伝子が配列番号1のヌクレオチド407 からヌクレオチド2851ま でに示されるヌクレオチド配列を含んで成る、請求項44に記載の方法。 46.前記選択マーカーが優性選択マーカーである、請求項42に記載の方法。 47.P.メタノリカ遺伝子の転写プロモーターを含んで成るDNA分子であっ て、前記遺伝子のコード配列を本質的に含まない前記DNA分子。 48.前記遺伝子がメタノール誘導性遺伝子である、請求項47に記載のDNA分 子。 49.前記遺伝子がアルコールオキシダーゼ、ジヒドロキシアセトンシンターゼ 、ホルメートデヒドロゲナーゼおよびカタラーゼ遺伝子から成る群より選ばれる 、請求項48に記載のDNA分子。 50.前記プロモーターが配列番号2のヌクレオチド24からヌクレオチド1354ま でに示されるヌクレオチド配列を含んで成る、請求項49に記載のDNA分子。 51.前記プロモーターが配列番号9のヌクレオチド91からヌクレオチド169 ま でに示されるヌクレオチド配列を含んで成る、請求項49に記載のDNA分子。 52.P.メタノリカ遺伝子の転写プロモーターを含んで成るDNA分子であっ て、前記プロモーターがP.メタノリカタンパク質以外のタンパク質をコードす るDNAセグメントに作用可能に連結さ れているDNA分子。 53.前記遺伝子がメタノール誘導性遺伝子である、請求項52に記載のDNA分 子。
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US639795P | 1995-11-09 | 1995-11-09 | |
| US60/006,397 | 1995-11-09 | ||
| US08/703,809 US5716808A (en) | 1995-11-09 | 1996-08-26 | Genetic engineering of pichia methanolica |
| US08/703,809 | 1996-08-26 | ||
| US08/703,807 US5955349A (en) | 1996-08-26 | 1996-08-26 | Compositions and methods for producing heterologous polypeptides in Pichia methanolica |
| US08/703,807 | 1996-08-26 | ||
| PCT/US1996/017944 WO1997017450A2 (en) | 1995-11-09 | 1996-11-08 | Compositions and methods for producing heterologous polypeptides in pichia methanolica |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2000500014A true JP2000500014A (ja) | 2000-01-11 |
Family
ID=27358122
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9518364A Ceased JP2000500015A (ja) | 1995-11-09 | 1996-11-08 | メチロトロープ性酵母におけるgad65の生成 |
| JP9518345A Pending JP2000500014A (ja) | 1995-11-09 | 1996-11-08 | ピヒア・メタノリカ中で異種ポリペプチドを生産するための組成物と方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9518364A Ceased JP2000500015A (ja) | 1995-11-09 | 1996-11-08 | メチロトロープ性酵母におけるgad65の生成 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US5965389A (ja) |
| EP (2) | EP0862640A2 (ja) |
| JP (2) | JP2000500015A (ja) |
| AU (2) | AU712650B2 (ja) |
| CA (2) | CA2237039A1 (ja) |
| WO (2) | WO1997017450A2 (ja) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015064517A1 (ja) * | 2013-10-28 | 2015-05-07 | 国立大学法人岐阜大学 | ギ酸脱水素酵素とその利用 |
| JP2018033450A (ja) * | 2007-12-19 | 2018-03-08 | グライコフィ, インコーポレイテッド | タンパク質の製造のための酵母株 |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6001597A (en) * | 1995-11-09 | 1999-12-14 | Zymogenetics, Inc. | Compositions and methods for producing heterologous polypeptides in Pichia methanolica |
| US6153424A (en) * | 1995-11-09 | 2000-11-28 | Zymogenetics, Inc. | Protease-deficient strains of Pichia methanolica |
| CA2261020C (en) * | 1996-07-17 | 2004-06-08 | Zymogenetics, Inc. | Preparation of pichia methanolica auxotrophic mutants |
| JP2002515746A (ja) * | 1996-07-17 | 2002-05-28 | ザイモジェネティクス,インコーポレイティド | ピヒア・メタノリカの形質転換 |
| BR9712348B1 (pt) | 1996-10-16 | 2013-06-18 | vetor de expressão, célula de bactéria ou levedura transformada ou transfectada, processo para produzir um polipeptídeo homólogo de fgf, composição farmacêutica, e, processos para estimular ex vivo células progenitoras de miócitos ou miócitos | |
| WO1999014347A1 (en) * | 1997-09-15 | 1999-03-25 | Zymogenetics, Inc. | PROTEASE-DEFICIENT STRAINS OF $i(PICHIA METHANOLICA) |
| US6183953B1 (en) | 1997-09-15 | 2001-02-06 | Zymogenetics, Inc. | Chromosomal mutagenesis in Pichia methanolica |
| JP2001516577A (ja) * | 1997-09-15 | 2001-10-02 | ザイモジェネティクス,インコーポレイティド | ピキア・メタノリカにおける染色体の突然変異誘発 |
| DE69933113D1 (de) * | 1998-02-19 | 2006-10-19 | Kirin Brewery | Promotor der dihydroxyacetonsynthase aus candida biodinii |
| US6730499B1 (en) * | 1998-07-03 | 2004-05-04 | Research Corporation Technologies, Inc. | Promoter for the Pichia pastoris formaldehyde dehydrogenase gene FLD1 |
| JP4511728B2 (ja) * | 1998-07-03 | 2010-07-28 | リサーチ コーポレイション テクノロジーズ,インコーポレイテッド | メチロトローフ酵母由来のホルムアルデヒドデヒドロゲナーゼ遺伝子 |
| US6468781B1 (en) * | 1999-07-08 | 2002-10-22 | Bristol-Myers Squibb Company | Stereoselective reductive amination of ketones |
| EA006501B1 (ru) | 1998-09-23 | 2005-12-29 | Займодженетикс, Инк. | Полипептиды zalpha 11 рецептора цитокина человека класса i, кодирующие их полинуклеотиды и способы их применения |
| EP1642972B1 (en) | 1999-01-07 | 2009-12-30 | ZymoGenetics, Inc. | Therapeutic uses of BR43X2 soluble receptors |
| US7833529B1 (en) | 1999-01-07 | 2010-11-16 | Zymogenetics, Inc. | Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor |
| RU2346951C2 (ru) | 1999-03-09 | 2009-02-20 | Займодженетикс, Инк. | Выделенный полипептид, связывающий рецептор zalpha11-лиганда (варианты), кодирующий его полинуклеотид (варианты), вектор экспрессии (варианты) и клетка-хозяин (варианты) |
| MXPA02000160A (es) * | 1999-06-24 | 2003-10-14 | Zymogenetics Inc | Promotor y terminador de la gliceraldehido3-fosfato deshidrogenasa 1 de la pichia methanolica. |
| EP2241623A3 (en) | 1999-07-07 | 2010-12-01 | ZymoGenetics, Inc. | Monoclonal antibody against a human cytokine receptor |
| JP2003509024A (ja) * | 1999-09-08 | 2003-03-11 | ザイモジェネティクス,インコーポレイティド | ピチア・メタノリカグリセルアルデヒド−3−リン酸デヒドロゲナーゼ2プロモーター及びターミネーター |
| US6348331B1 (en) | 1999-09-08 | 2002-02-19 | Zymogenetics, Inc. | Pichia methanolica glyceraldehyde-3-phosphate dehydrogenase 2 promoter |
| EP1234047A1 (en) * | 1999-12-01 | 2002-08-28 | Centre for Translational Research in Cancer | Drug inducible system and use thereof |
| AU2292601A (en) | 1999-12-23 | 2001-07-03 | Zymogenetics Inc. | Novel cytokine zcyto18 |
| AU2001239205A1 (en) * | 2000-03-10 | 2001-09-17 | Novozymes A/S | Compositions and methods for producing high yields of heterologous polypeptides in a pichia cell |
| CN1654956A (zh) | 2000-05-04 | 2005-08-17 | 耶鲁大学 | 用于筛选蛋白活性的高密度蛋白阵列 |
| JP2004501628A (ja) | 2000-06-26 | 2004-01-22 | ザイモジェネティクス,インコーポレイティド | サイトカイン受容体zcytor17 |
| WO2002066516A2 (en) | 2001-02-20 | 2002-08-29 | Zymogenetics, Inc. | Antibodies that bind both bcma and taci |
| WO2002081650A2 (en) * | 2001-04-05 | 2002-10-17 | The Board Of Regents Of The University Of Nebraska | Alcohol oxidase 1 regulatory nucleotide sequences for heterologous gene expression in yeast |
| CN1527720A (zh) * | 2001-05-11 | 2004-09-08 | Ү³��ѧ | 利用蛋白组芯片全面分析蛋白活性 |
| ATE446771T1 (de) | 2001-05-24 | 2009-11-15 | Zymogenetics Inc | Taci-immunoglobulin-fusionsproteine |
| WO2003011285A1 (en) * | 2001-08-01 | 2003-02-13 | Merck & Co., Inc. | BENZIMIDAZO[4,5-f]ISOQUINOLINONE DERIVATIVES |
| ES2466024T3 (es) | 2001-10-10 | 2014-06-09 | Ratiopharm Gmbh | Remodelación y glicoconjugación de factor de crecimiento de fibroblastos (FGF) |
| MXPA04004167A (es) | 2001-11-05 | 2004-07-08 | Zymogenetics Inc | Antagonistas de interleucina-21. |
| AU2003225525B2 (en) | 2002-01-18 | 2008-07-24 | Zymogenetics, Inc. | Novel cytokine zcytor17 ligand |
| US7494804B2 (en) | 2002-01-18 | 2009-02-24 | Zymogenetics, Inc. | Polynucleotide encoding cytokine receptor zcytor17 multimer |
| JP4409962B2 (ja) | 2002-04-19 | 2010-02-03 | ザイモジェネティクス,インコーポレイティド | サイトカイン受容体 |
| US20070026485A1 (en) | 2003-04-09 | 2007-02-01 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
| WO2004108890A2 (en) * | 2003-05-30 | 2004-12-16 | New Century Pharmaceuticals, Inc. | Dilute methanol -or ethanol- induced production of polypeptides in microorganisms |
| US20040248323A1 (en) | 2003-06-09 | 2004-12-09 | Protometrix, Inc. | Methods for conducting assays for enzyme activity on protein microarrays |
| CN1910200A (zh) | 2003-08-07 | 2007-02-07 | 津莫吉尼蒂克斯公司 | Il-28和il-29的均一化制剂 |
| BRPI0513865A (pt) | 2004-07-29 | 2008-05-20 | Zymogenetics Inc | métodos para tratar cáncer, para inibir a progressão de cáncer, para retardar o começo de cáncer, para reduzir a severidade de cáncer, e para inibir pelo menos uma das condições ou sintomas de cáncer, do linfoma não-hodgkin, do mieloma múltiplo, e de tumores da cabeça e o pescoço |
| EP1781784A2 (en) | 2004-08-02 | 2007-05-09 | BASF Plant Science GmbH | Method for isolation of transcription termination sequences |
| JP2008532931A (ja) | 2005-02-08 | 2008-08-21 | ザイモジェネティクス, インコーポレイテッド | 抗il−20、抗il−22および抗il−22ra抗体ならびに結合パートナー、ならびに炎症における使用法 |
| JP2008544746A (ja) | 2005-05-12 | 2008-12-11 | ザイモジェネティクス, インコーポレイテッド | 免疫応答を調節するための組成物および方法 |
| US8808696B2 (en) | 2005-08-09 | 2014-08-19 | Ares Trading S.A. | Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules |
| WO2007019575A2 (en) | 2005-08-09 | 2007-02-15 | Zymogenetics, Inc. | Methods for treating b-cell malignancies using taci-ig fusion molecule |
| PT1931697E (pt) | 2005-09-28 | 2010-12-06 | Zymogenetics Inc | Antagonistas de il-17a e il-17f e processos para a sua utilização |
| CA2651791A1 (en) | 2006-05-15 | 2007-11-22 | Ares-Trading S.A. | Methods for treating autoimmune diseases using a taci-ig fusion molecule |
| EP2225267B1 (en) | 2007-11-21 | 2015-01-14 | Roskilde Universitet | Polypeptides comprising an ice-binding activity |
| EP2245052B1 (en) | 2008-01-25 | 2017-05-24 | Aarhus Universitet | Selective exosite inhibition of papp-a activity against igfbp-4 |
| US20110275535A1 (en) | 2008-12-16 | 2011-11-10 | Novartis Ag | Yeast Display Systems |
| WO2013116771A1 (en) | 2012-02-01 | 2013-08-08 | Synthetic Genomics, Inc. | Materials and methods for the synthesis of error-minimized nucleic acid molecules |
| WO2014202089A2 (en) | 2013-06-18 | 2014-12-24 | Roskilde Universitet | Variants of anti-freeze polypeptides |
| KR20160068972A (ko) * | 2013-11-15 | 2016-06-15 | 노파르티스 아게 | 잔여 세포 배양 불순물의 제거 |
| CN105400813A (zh) * | 2015-12-28 | 2016-03-16 | 江南大学 | 一种重组表达人谷氨酸脱羧酶的毕赤酵母基因工程菌 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4879231A (en) * | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4855231A (en) * | 1984-10-30 | 1989-08-08 | Phillips Petroleum Company | Regulatory region for heterologous gene expression in yeast |
| US4808537A (en) * | 1984-10-30 | 1989-02-28 | Phillips Petroleum Company | Methanol inducible genes obtained from pichia and methods of use |
| US5032516A (en) * | 1985-10-25 | 1991-07-16 | Phillips Petroleum Company | Pichia pastoris alcohol oxidase II regulatory region |
| US5166329A (en) * | 1985-10-25 | 1992-11-24 | Phillips Petroleum Company | DNA encoding the alcohol oxidase 2 gene of yeast of the genus Pichia |
| US4882279A (en) * | 1985-10-25 | 1989-11-21 | Phillips Petroleum Company | Site selective genomic modification of yeast of the genus pichia |
| DE3789866T2 (de) * | 1987-07-17 | 1994-09-22 | Rhein Biotech Gesellschaft Fuer Neue Biotechnologische Prozesse Und Produkte Mbh, 40595 Duesseldorf | DNA-Moleküle, die für FMDH-Kontrollabschnitte und Strukturgene für ein Protein mit FMDH-Aktivität kodieren, sowie deren Anwendung. |
| NZ228948A (en) * | 1988-05-13 | 1991-06-25 | Phillips Petroleum Co | Hbv particles containing s and pre-s 2 proteins and recombinant processes for their production in yeast cells |
| JPH06500470A (ja) * | 1990-09-04 | 1994-01-20 | メルク エンド カンパニー インコーポレーテッド | メチロトローフ酵母細胞におけるインスリン様成長因子の産生 |
| US5512447A (en) * | 1990-09-07 | 1996-04-30 | The Regents Of The University Of California | Methods for the diagnosis and treatment of diabetes |
| US6682906B1 (en) * | 1990-09-21 | 2004-01-27 | The Regents Of The University Of California | Cloned glutamic acid decarboxylase |
| US5475086A (en) * | 1990-09-21 | 1995-12-12 | The Regents Of The University Of California | Cloned glutamic acid decarboxylase peptides |
| CA2103159A1 (en) * | 1991-05-15 | 1992-11-16 | Ake Lernmark | Cloning and expression of human islet glutamic acid decarboxylase autoantigen |
| DK88093D0 (da) * | 1993-07-28 | 1993-07-28 | Novo Nordisk As | Stabilt praeparat |
-
1996
- 1996-11-08 AU AU76737/96A patent/AU712650B2/en not_active Ceased
- 1996-11-08 US US08/747,108 patent/US5965389A/en not_active Expired - Fee Related
- 1996-11-08 AU AU11582/97A patent/AU1158297A/en not_active Abandoned
- 1996-11-08 JP JP9518364A patent/JP2000500015A/ja not_active Ceased
- 1996-11-08 CA CA002237039A patent/CA2237039A1/en not_active Abandoned
- 1996-11-08 EP EP96942740A patent/EP0862640A2/en not_active Withdrawn
- 1996-11-08 WO PCT/US1996/017944 patent/WO1997017450A2/en not_active Ceased
- 1996-11-08 JP JP9518345A patent/JP2000500014A/ja active Pending
- 1996-11-08 CA CA002237120A patent/CA2237120C/en not_active Expired - Fee Related
- 1996-11-08 WO PCT/US1996/017980 patent/WO1997017451A2/en not_active Ceased
- 1996-11-08 EP EP96939604A patent/EP0889966A1/en not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018033450A (ja) * | 2007-12-19 | 2018-03-08 | グライコフィ, インコーポレイテッド | タンパク質の製造のための酵母株 |
| WO2015064517A1 (ja) * | 2013-10-28 | 2015-05-07 | 国立大学法人岐阜大学 | ギ酸脱水素酵素とその利用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2237120C (en) | 2005-03-01 |
| CA2237120A1 (en) | 1997-05-15 |
| WO1997017450A3 (en) | 1997-07-10 |
| AU7673796A (en) | 1997-05-29 |
| WO1997017451A2 (en) | 1997-05-15 |
| US5965389A (en) | 1999-10-12 |
| AU712650B2 (en) | 1999-11-11 |
| EP0889966A1 (en) | 1999-01-13 |
| EP0862640A2 (en) | 1998-09-09 |
| JP2000500015A (ja) | 2000-01-11 |
| AU1158297A (en) | 1997-05-29 |
| CA2237039A1 (en) | 1997-05-15 |
| WO1997017451A3 (en) | 1997-07-10 |
| WO1997017450A2 (en) | 1997-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2000500014A (ja) | ピヒア・メタノリカ中で異種ポリペプチドを生産するための組成物と方法 | |
| US5716808A (en) | Genetic engineering of pichia methanolica | |
| US5888768A (en) | Compositions and methods for producing heterologous polypeptides in Pichia methanolica | |
| US5736383A (en) | Preparation of Pichia methanolica auxotrophic mutants | |
| CA2261020C (en) | Preparation of pichia methanolica auxotrophic mutants | |
| AU718510B2 (en) | Transformation of pichia methanolica | |
| Meyer et al. | Galactokinase encoded by GAL1 is a bifunctional protein required for induction of the GAL genes in Kluyveromyces lactis and is able to suppress the gal3 phenotype in Saccharomyces cerevisiae | |
| Pretorius et al. | The impact of yeast genetics and recombinant DNA technology on the wine industry-a review | |
| US4626505A (en) | Selectable markers for yeast transformation | |
| JPS62104585A (ja) | ピチア属酵母の部位選択的ゲノム修飾 | |
| JP3433295B2 (ja) | キシリトールの製造のための組換え方法および宿主 | |
| US6153424A (en) | Protease-deficient strains of Pichia methanolica | |
| Otero et al. | Efficient selection of hygromycin-B-resistant Yarrowia lipolytica transformants | |
| JP2018157814A (ja) | シュードザイマ・アンタクティカの新規菌株 | |
| JP3478396B2 (ja) | 黒色アスペルギルスカタラーゼ−rの産生 | |
| Olsson et al. | Silencing MIG1 in Saccharomyces cerevisiae: effects of antisense MIG1 expression and MIG1 gene disruption | |
| US5204252A (en) | Candida tropicalis transformation system | |
| JP6206408B2 (ja) | シゾサッカロミセス・ポンベ変異体の形質転換体、およびクローニングベクター | |
| KR20010023688A (ko) | 효모에서 폴리펩티드를 생산하는 발현 벡터 | |
| US6001597A (en) | Compositions and methods for producing heterologous polypeptides in Pichia methanolica | |
| DE69832504T2 (de) | Verfahren zur Veränderung eines chrmosomalen Locus von Pichia methanolica-Zellen | |
| EP0946734B1 (en) | Preparation of pichia methanolica auxotrophic mutants | |
| DE69735369T2 (de) | Herstellung von auxotrophen mutanten von pichia methanolica | |
| US6183953B1 (en) | Chromosomal mutagenesis in Pichia methanolica | |
| CN121204166A (zh) | 用于基因编辑的组合物及其在基因编辑中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061107 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070202 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070402 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070507 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080115 |